Treatable Traits in Interstitial Lung Disease

Recruiting N/A Interventional Study
Interstitial Lung Diseases (ILD)
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
110 (estimated)
Sponsor
The University of Western Australia · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The goal of this clinical trial is to learn if a personalised treatment model of care "treatable traits" can improve quality of life and disease progression in patients with interstitial lung disease. The main question it aims to answer is, will providing a treatable traits model of care improve health-related quality of life (HRQoL) (primary outcome), symptoms, anxiety, physical activity, and bo…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: Patients with a new or pre-existing diagnosis of fibrotic ILD who receive care via the Fiona Stanley Hospital (FSH) or Sir Charles Gairdner Hospital (SCGH) ILD service will be invited to participate. This ILD diagnosis must be made through an ILD MDT. Included participants will …
Contacts

Megan Harrison, MBSS (Hons) FRACP

+61 08 6457 3333

megan.harrison@health.wa.gov.au

CONTACT

Yuben Moodley, MBSS, FRACP, MD, PHD

61086152 2222

yuben.moodley@health.wa.gov.au

CONTACT